Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GYNIX vs CANDEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Coagulative necrosis of tissue via trichloroacetic acid; chemical cauterization of epithelial cells.
Candesartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to vasodilation and reduced blood pressure.
Cervical inflammation,Vaginal infections,Treatment of genital warts,Chemical cautery of skin lesions
Hypertension,Heart failure (NYHA class II-IV and left ventricular systolic dysfunction, to reduce cardiovascular mortality)
1 vaginal tablet (100 mg) once daily at bedtime for 7 days
Adults: 150 mg orally once daily
Terminal half-life is 2.5-3 hours in patients with normal renal function; prolonged to 6-8 hours in moderate renal impairment (Cr Cl 30-50 m L/min) and up to 12-15 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life is 20-30 hours (mean 24 hours) in adults; prolonged in hepatic impairment (up to 50 hours) and requires dose adjustment.
Not metabolized; acts locally via direct chemical action.
Primarily metabolized by CYP2C9 to an inactive metabolite; also undergoes O-deethylation. Minimal hepatic metabolism, primarily excreted unchanged in bile and urine.
Primarily renal (approximately 60-80% as unchanged drug) and biliary (20-30% as metabolites; unchanged drug not detected in bile). Fecal elimination accounts for <5%.
Primarily hepatic metabolism via CYP2C9, with <1% excreted unchanged in urine. Approximately 70-80% eliminated in feces as metabolites, 20-30% in urine as metabolites.
Approximately 20-30% bound to albumin with negligible binding to alpha-1-acid glycoprotein.
99% bound to albumin (primarily), also to alpha-1-acid glycoprotein.
Apparent Vd is 0.8-1.1 L/kg (range 0.6-1.3 L/kg), indicating extensive tissue distribution (e.g., lung, liver, bone).
Extensive: 1.5-2 L/kg, indicating wide distribution into tissues including skin, nails, and adipose tissue. Accumulates in stratum corneum and nails.
Oral: 85-95% (immediate-release) and 70-80% (sustained-release due to first-pass effect). Vaginal: 5-10% (minimal systemic absorption). IV: 100%.
Oral: 99% (well absorbed); food does not affect absorption. No IV formulation due to poor water solubility; not administered topically for systemic effects.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min: use with caution, consider alternative therapy.
Cr Cl 30-60 m L/min: 100 mg once daily; Cr Cl 15-29 m L/min: 50 mg once daily; Cr Cl <15 m L/min: 50 mg every 48 hours
Mild to moderate hepatic impairment (Child-Pugh A or B): no adjustment. Severe (Child-Pugh C): contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: 100 mg once daily; Child-Pugh C: not recommended
Not approved for use in pediatric patients.
Not established for children <18 years of age
No dose adjustment required; use same as adult dosing.
No specific adjustment required; consider renal function and potential for increased sensitivity
None.
Fetal toxicity: Drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.
Avoid contact with normal tissue; risk of chemical burns; not for use on neoplastic lesions.
Fetal toxicity,Hypotension in volume-depleted patients,Renal function impairment,Hyperkalemia,Avoid concomitant use with aliskiren in patients with diabetes
Hypersensitivity to trichloroacetic acid; pregnancy (relative); use on malignant tissue.
Hypersensitivity to candesartan or any component,Concomitant use with aliskiren in patients with diabetes,Pregnancy
No known food interactions with topical use. However, avoid concurrent use of iodine-containing supplements or medications, as it may increase systemic iodine load.
No significant food interactions. Grapefruit juice does not interact. Avoid salt substitutes with potassium.
First trimester: Inadequate human data; animal studies not available. Theoretical risk based on pharmacologic action. Second and third trimesters: No known fetal harm from topical use. Systemic absorption minimal.
Teratogenic risk profile for Candesartan (CANDEX) is based on its mechanism as an angiotensin II receptor blocker (ARB). First trimester: No increased risk of major congenital malformations from first-trimester exposure based on human data, but animal studies show fetal toxicity at high doses. Second and third trimesters: Known to cause fetal renal dysfunction, oligohydramnios, skull ossification defects, and neonatal renal failure. Use is contraindicated in pregnancy, especially after 20 weeks gestation.
No data on excretion in human milk. Expected minimal systemic absorption. Use caution if applied to breast area. M/P ratio unknown.
Excretion into breast milk is unknown; limited data may be available for similar ARBs but M/P ratio is not established. Due to risk of neonatal renal effects, use during breastfeeding is not recommended, especially in preterm infants or those with renal impairment. Alternative agents preferred.
No dose adjustment necessary for topical use. Systemic absorption negligible.
Pharmacokinetic changes in pregnancy (increased volume of distribution, renal blood flow) may require dose adjustments. However, due to fetotoxicity, candesartan is contraindicated in pregnancy, and no dose recommendation is provided. Alternative antihypertensives such as labetalol or nifedipine are preferred.
GYNIX (povidone-iodine) is a topical antiseptic. Avoid use in patients with iodine hypersensitivity or thyroid disorders (e.g., Hashimoto's thyroiditis). Prolonged use on large wounds may cause iodine absorption and thyroid dysfunction. Monitor for local irritation or allergic contact dermatitis.
Candesartan is contraindicated in pregnancy (category D). Monitor renal function and electrolytes, especially in renal artery stenosis, heart failure, or volume depletion. May cause hypotension, especially in CHF patients. Dual blockade with ACEi increases risk of hyperkalemia and renal impairment.
Do not use if you are allergic to iodine or have a thyroid condition.,For external use only. Avoid contact with eyes, mouth, or open wounds unless directed.,Discontinue and inform your doctor if you develop rash, itching, or swelling.,Store at room temperature away from light. Do not freeze or heat.,Not for use on deep or puncture wounds, or severe burns without medical advice.
Take exactly as prescribed, usually once daily.,Avoid potassium supplements or salt substitutes containing potassium without medical advice.,If you become pregnant, stop taking and contact your doctor immediately.,May cause dizziness or lightheadedness; avoid driving until you know how you react.,Report any signs of angioedema (swelling of face, lips, throat) or fainting.,Stay hydrated, especially if experiencing diarrhea or vomiting.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GYNIX vs CANDEX, answered by our medical review team.
GYNIX is a Polyene Antifungal that works by Coagulative necrosis of tissue via trichloroacetic acid; chemical cauterization of epithelial cells.. CANDEX is a Topical Antifungal and Corticosteroid that works by Candesartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to vasodilation and reduced blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GYNIX and CANDEX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GYNIX is: 1 vaginal tablet (100 mg) once daily at bedtime for 7 days. The standard adult dose of CANDEX is: Adults: 150 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GYNIX and CANDEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GYNIX is classified as Category C. First trimester: Inadequate human data; animal studies not available. Theoretical risk based on pharmacologic action. Second and third trimesters: No known fetal harm from topical . CANDEX is classified as Category C. Teratogenic risk profile for Candesartan (CANDEX) is based on its mechanism as an angiotensin II receptor blocker (ARB). First trimester: No increased risk of major congenital malf. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.